Sitemap
- Home
- Dermatology
- Atopic Dermatitis
- Articles
- Resources
- DE:RM – Dermatology Excellence: Redefining Management
- Expert Insights on Advancing the Conversation on Disease Modification in Atopic Dermatitis
- Hot Topics in Atopic Dermatitis
- Dupixent (dupilumab) Resources
- Inside Atopic Dermatitis: The Dupixent (Dupilumab) Podcast Series
- DUPIXENT® (dupilumab) Atopic Dermatitis Patient Support Resources
- Tools
- Atopic Dermatitis
- Respiratory
- Cardiology
- Dyslipidaemia
- Articles
- Praluent® (alirocumab) mechanism of action
- Cardiovascular outcomes for diabetes patients Praluent® (alirocumab)
- ODYSSEY OUTCOMES Efficacy Praluent® (alirocumab)
- FH I & FH II Studies Praluent® (alirocumab)
- ODYSSEY OUTCOMES Safety Profile Praluent® (alirocumab)
- Therapeutic indications for Praluent® (alirocumab)
- NICE and SMC Guidance Praluent® (alirocumab)
- Dosing options – customise your patient’s treatment with Praluent® (alirocumab)
- ODYSSEY OUTCOMES Trial Design Praluent® (alirocumab)
- Praluent® (alirocumab) Administration
- Specific characteristics of Praluent® (alirocumab)
- Unmet Needs in Dyslipidaemia
- Resources
- Education
- Articles
- Dyslipidaemia
- Rare Disease
- Other Topics
- Vaccines
- Diabetes
- Type 1 Diabetes
- Type 2 Diabetes
- Articles
- Hospitalisation rates with basal insulin in adults with T2D
- Help Managing Insulin-Related Weight Gain in Type 2 Diabetes: Practical Guidance
- Patient satisfaction with Toujeo (insulin glargine 300 Units/mL) in adults with T2D
- The BRIGHT Study: Comparing Toujeo® (insulin glargine 300 U/mL) and Insulin Degludec 100 U/mL
- Head to Head Studies
- The Importance of Glycaemic Control: Strategies to Support People with Type 2 Diabetes
- Events
- Education
- Articles
- Transplant
- Transplant
- Articles
- Education
- Patient Case Study Presentations - EBMT 2025
- EBMT 2024: The late effects of chronic GvHD: The challenge of long-term management
- UK InTEN GvHD Forum - Genital GvHD Session
- UK InTEN GvHD Forum - Ocular GvHD Session
- EBMT 2024: QoL and chronic GvHD
- UK InTEN GvHD Forum - Lung GvHD Session
- UK InTEN GvHD Forum - Real World: UK Clinical Insights
- EBMT 2024: Treatment of steroid refractory chronic GvHD
- UK InTEN GvHD Forum - Skin GvHD Session
- InTen Nurse Forum - ACCEND Framework
- EBMT 2024: Frontline treatment of chronic GvHD
- InTen Nurse Forum: What is chronic GvHD?
- Patient Case Study 8: Treatment of Severe cGVHD
- Patient Case Study 9: Treatment of cGVHD with Steroid-related Complications
- EBMT 2024: Roundtable: Exploring clinical cases
- EBMT 2024: Expanding the cGvHD treatment paradigm with novel therapeutics
- EBMT 2024: Advances in the biology of chronic GvHD
- EBMT 2024: Pulmonary chronic GvHD: The need for early identification and improved management
- Transplant
- Oncology
- Multiple Myeloma
- Articles
- SARCLISA® (isatuximab) in Clinical Practice Professor Karthik Ramasamy: Frail Case Study Review
- About Multiple Myeloma
- SARCLISA® (isatuximab) in Clinical Practice Translating IMROZ into Clinic: Presented by Dr Ceri Bygrave
- SARCLISA® (isatuximab) in Clinical Practice Dr Sally Moore: Borderline Case Study Overview
- SARCLISA® (isatuximab) in Clinical Practice Professor Karthik Ramasamy: Borderline Case Study Review
- SARCLISA® (isatuximab) in Clinical Practice Case Studies and Translating IMROZ into Clinic
- Articles
- Multiple Myeloma
- Neurology
- Products
- Avaxim®
- Cerdelga®▼(Eliglustat)
- Efluelda TIV-HD▼
- Supemtek TIVr
- Vaxigrip Trivalent Influenza Vaccine
- Cablivi®
- Avaxim® Junior hepatitis A vaccine (inactivated, adsorbed)
- Praluent®
- Nuvaxovid JN.1▼ COVID-19 vaccine (Recombinant Adjuvanted)
- TZIELD▼ (teplizumab)
Infusion Training Workshop
Support Materials
Benefits of Testing
Eligible Patients
Efficacy and Safety
Who to Test
Diabetes UK Professional Conference (DUK)
Useful Links
Monitoring Guidance
Mechanism of Actions
Dosing and Administration
- Benefits for Patients
- T1D vs T2D
- Burden of T1D
- About T1D
For HCPs
For your Patients
Testing Process
- Beyfortus®▼ (nirsevimab)
- Myozyme®
- Repevax®
- Revaxis®
- Cerezyme®
- REZUROCK®▼
- Lantus®
- Verorab®
- DUPIXENT (dupilumab) COPD
- Toujeo®
- Trurapi®▼
- Typhim Vi (Typhoid Polysaccharide Vaccine)®
- SARCLISA® (isatuximab) RRMM
- Fabrazyme®
- MenQuadfi
- Dupixent® (dupilumab) Atopic Dermatitis
- Stamaril® (Yellow Fever Vaccine Live)
- DUPIXENT® (dupilumab) Severe Asthma
- SARCLISA® (isatuximab) Ti NDMM
- Clexane®
- DUPIXENT® (dupilumab) Severe Chronic Rhinosinusitis with Nasal Polyps
- Nexviadyme® ▼
- Aldurazyme®
- Dupixent® (dupilumab) Prurigo Nodularis
- Typhoid
- Other Neurology Topics
- Polio
- Thyroid Cancer
- Hypnotics
- indications.angina
- Acquired Thrombotic Thrombocytopenia Purpura Attp
- indications.urticaria
- Hepatitis A Typhoid
- indications.chronic_spontaneous_urticaria_csu
- Antiparasitic
- Tdap - Booster
- indications.post_myocardial_infarction
- Atopic Dermatitis
- Dtwcp Hib Ipv Hep B Hexa Whole Cell Primary Series
- Hyperuricaemia
- Schizophrenia
- Other Transplant Topics
- indications.parkinson’s_disease_pd
- Travel
- Other Rare Disease Topics
- Influenza
- Central nervous system
- Rabies
- Asthma
- Haemophilia B
- Acellular Pertussis
- Type 2 Diabetes
- Better Care for Rare
- Oral Polio Vaccine
- Diphteria Tetanus Booster
- Prostate Cancer
- indications.trachomatis_infections
- indications.blood_cancer
- indications.amyotrophic_lateral_sclerosis_als
- Tetanus
- Cholera
- indications.analgesics
- Bipolar
- Anti Infectives
- Hepatitis A
- indications.chronic_inflammatory_demyelinating_polyneuropathy_cidp
- Other Dermatology Topics
- Flu Seasonal Standard Dose
- indications.head_and_neck_cancer
- Hepatitis B
- Coronavirus Disease 2019
- Arrhythmia
- Other Diabetes Topics
- Acid Sphingomylenase Deficiency Niemann Pick
- Hyperkalaemia
- indications.peripheral_arterial_disease
- indications.anesthetic
- Colorectal Cancer
- Skin Cancer
- indications.tuberculosis_test
- Corticosteroids
- indications.cervical_cancer
- indications.gastric_adenocarcinoma
- Dengue
- Rabies Immunoglobulins
- Heart failure
- Dtacp Tri Acellular Primary Series
- Chronic Kidney Disease Ckd
- Yellow Fever
- Dyslipidaemia
- Biosurgery
- Respiratory Syncytial Virus
- Hypothyroidism
- Eosinophilic Oesophagitis
- Dtacp Hib Ipv Hep B Hexa Acellular Primary Series
- Rheumatoid Arthritis
- Diphtheria
- Haemophilia A
- Injectable Polio Vaccine
- Hypertension
- Chronic Rhinosinusitis With Nasal Polyps Crswnp
- Meningococcal disease
- Tdacp Ipv Booster
- Pompe
- Achondroplasia
- Dtacp Hib Ipv Penta Acellular Primary Series
- Integrated Diabetes Care
- Immune Thrombocytopenic (ITP)
- Type 1 Diabetes
- indications.renal_disease
- Benign prostatic hyperplasia (BPH)
- COPD
- indications.myasthenia_gravis_mg
- Cardiac Stimulants
- indications.neutrophil_deficiency
- Multiple Myeloma
- Anxiety
- Other Cardiology Topics
- Dtacp Ipv Tetra Acellular Primary Series
- Gaucher
- Breast Cancer
- Epilepsy
- Mucopolysaccharidosis Mps
- Lung Cancer
- General Topics
- Haemophilus Influenza
- indications.psoriatic_arthritis
- indications.allergic_rhinitis
- GM2 Gangliosidosis
- Multiple Sclerosis
- Payor
- Other Topics
- Tetanus Booster
- indications.griep
- Gastroesophageal Reflux Disease Gerd
- Academy of Knowledge
- Dtwcp Hib Hep B Penta Whole Cell Primary Series
- Leukaemia/Lymphoma
- Other Oncology Topics
- Other Vaccines Topics
- Fabry
- indications.airway_mucus_hypersecretion
- Solid Tumor Malignancies
- Other Rare Blood Disorders Topics
- Prurigo Nodularis
- Transplant
- Japanese Encephalitis
- indications.acromegaly
- Cold Agglutinin Disease (CAD)
- indications.neuroendocrine_tumors
- Td Ipv Booster
- Polymyalgia Rheumatica (PMR)
- Hunter Syndrome
- Anti Inflammatory
- indications.diuretic
- indications.dengue_test
- Thrombosis
- Therapeutic Areas
- Sitemap
- Sign Up
- Sign In
- Terms of Use
- Privacy Policy
- Cookie Policy